AbbVie Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ABBV New York 2834 https://www.abbvie.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AbbVie Inc

Biotech ETFs Hit New Highs on Deal Activities - Dec 10th, 2019 3:10 pm
Merck Stock Is On An Upswing In 2019 — Should You Buy This Pharma Stock? - Dec 10th, 2019 1:00 pm
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know - Dec 9th, 2019 10:45 pm
World's largest biotech company to move up to BioMed's big South City project - Dec 9th, 2019 3:03 pm
J&J Presents Data on CAR-T Therapy Drug and Imbruvica at ASH - Dec 9th, 2019 2:42 pm
Sanofi to Buy Synthorx for $2.5B to Boost Cancer Portfolio - Dec 9th, 2019 2:28 pm
3 Top Dividend Stocks to Maximize Your Retirement Income - December 09, 2019 - Dec 9th, 2019 2:22 pm
Adaptive and AbbVie Partner Across Multiple Myeloma Trials to Measure Minimal Residual Disease Using the clonoSEQ® Assay - Dec 9th, 2019 1:00 pm
AbbVie and Scripps Research announce collaboration to develop a broad range of new therapeutics - Dec 9th, 2019 1:00 pm
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) - Dec 8th, 2019 12:30 pm
More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unresponsive to Prior Regimen - Dec 7th, 2019 2:00 pm
Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL) - Dec 7th, 2019 12:33 pm
IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) - Dec 7th, 2019 12:30 pm
Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting - Dec 6th, 2019 9:30 pm
Belgium's UCB says psoriasis drug beats AbbVie's Humira in trial - Dec 6th, 2019 12:27 pm
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis - Dec 6th, 2019 11:00 am
J&J Stock Witnesses Volatility in '19: What to Expect in 2020 - Dec 5th, 2019 2:07 pm
AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should You Buy It? - Dec 4th, 2019 3:00 pm
Where to Buy Booming Biotech ETFs - Dec 3rd, 2019 2:26 pm
[video]AbbVie Affirmed Overweight at Piper Jaffray on Potential of Arthritis Drug - Dec 3rd, 2019 10:06 am